#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=The MDS-CVI is primarily a data-collection tool .
3-1	15-18	The	object[3]	new[3]	coref	3-4[4_3]
3-2	19-26	MDS-CVI	object[3]	new[3]	_	_
3-3	27-29	is	_	_	_	_
3-4	30-39	primarily	object[4]	giv[4]	coref	10-5[58_4]
3-5	40-41	a	object[4]	giv[4]	_	_
3-6	42-57	data-collection	object[4]	giv[4]	_	_
3-7	58-62	tool	object[4]	giv[4]	_	_
3-8	63-64	.	_	_	_	_

#Text=However , when completing the registry , healthcare professionals are reminded of important actions that can be carried out in people with risk factors such as older age , female sex , and obesity , which increase their likelihood of having CVD .
4-1	65-72	However	_	_	_	_
4-2	73-74	,	_	_	_	_
4-3	75-79	when	_	_	_	_
4-4	80-90	completing	_	_	_	_
4-5	91-94	the	abstract[5]	new[5]	_	_
4-6	95-103	registry	abstract[5]	new[5]	_	_
4-7	104-105	,	_	_	_	_
4-8	106-116	healthcare	organization|person[7]	new|new[7]	ana|coref|ana|coref	4-38[0_7]|6-1|4-38[0_7]|6-1
4-9	117-130	professionals	person[7]	new[7]	_	_
4-10	131-134	are	_	_	_	_
4-11	135-143	reminded	_	_	_	_
4-12	144-146	of	_	_	_	_
4-13	147-156	important	abstract[8]	new[8]	_	_
4-14	157-164	actions	abstract[8]	new[8]	_	_
4-15	165-169	that	_	_	_	_
4-16	170-173	can	_	_	_	_
4-17	174-176	be	_	_	_	_
4-18	177-184	carried	_	_	_	_
4-19	185-188	out	_	_	_	_
4-20	189-191	in	_	_	_	_
4-21	192-198	people	abstract[9]	new[9]	_	_
4-22	199-203	with	abstract[9]	new[9]	_	_
4-23	204-208	risk	abstract[9]|abstract|abstract[11]	new[9]|new|new[11]	_	_
4-24	209-216	factors	abstract[9]|abstract[11]	new[9]|new[11]	_	_
4-25	217-221	such	abstract[9]|abstract[11]	new[9]|new[11]	_	_
4-26	222-224	as	abstract[9]|abstract[11]	new[9]|new[11]	_	_
4-27	225-230	older	abstract[9]|abstract[11]|abstract[12]|abstract[13]	new[9]|new[11]|new[12]|new[13]	ana|ana	6-5[0_13]|6-5[0_13]
4-28	231-234	age	abstract[9]|abstract[11]|abstract[12]|abstract[13]	new[9]|new[11]|new[12]|new[13]	_	_
4-29	235-236	,	abstract[9]|abstract[11]|abstract[13]	new[9]|new[11]|new[13]	_	_
4-30	237-243	female	abstract[9]|abstract[11]|abstract[13]|abstract[14]	new[9]|new[11]|new[13]|new[14]	_	_
4-31	244-247	sex	abstract[9]|abstract[11]|abstract[13]|abstract[14]	new[9]|new[11]|new[13]|new[14]	_	_
4-32	248-249	,	abstract[9]|abstract[11]|abstract[13]	new[9]|new[11]|new[13]	_	_
4-33	250-253	and	abstract[9]|abstract[11]|abstract[13]	new[9]|new[11]|new[13]	_	_
4-34	254-261	obesity	abstract[9]|abstract[11]|abstract[13]|abstract	new[9]|new[11]|new[13]|new	coref	8-7[42_0]
4-35	262-263	,	_	_	_	_
4-36	264-269	which	_	_	_	_
4-37	270-278	increase	_	_	_	_
4-38	279-284	their	person|abstract[17]	giv|new[17]	coref|coref	6-1[27_0]|6-1[27_0]
4-39	285-295	likelihood	abstract[17]	new[17]	_	_
4-40	296-298	of	_	_	_	_
4-41	299-305	having	_	_	_	_
4-42	306-309	CVD	abstract	new	coref	5-7
4-43	310-311	.	_	_	_	_

#Text=Activities to promote health , prevent CVD , and diagnose it at earlier stages will help halt or delay disease progress .
5-1	312-322	Activities	abstract	new	_	_
5-2	323-325	to	_	_	_	_
5-3	326-333	promote	_	_	_	_
5-4	334-340	health	abstract	new	ana	5-11
5-5	341-342	,	_	_	_	_
5-6	343-350	prevent	_	_	_	_
5-7	351-354	CVD	event	giv	coref	7-6
5-8	355-356	,	_	_	_	_
5-9	357-360	and	_	_	_	_
5-10	361-369	diagnose	_	_	_	_
5-11	370-372	it	abstract	giv	coref	6-8[29_0]
5-12	373-375	at	_	_	_	_
5-13	376-383	earlier	abstract[23]	new[23]	coref	8-13[43_23]
5-14	384-390	stages	abstract[23]	new[23]	_	_
5-15	391-395	will	_	_	_	_
5-16	396-400	help	_	_	_	_
5-17	401-405	halt	_	_	_	_
5-18	406-408	or	_	_	_	_
5-19	409-414	delay	_	_	_	_
5-20	415-422	disease	abstract|abstract[25]	new|new[25]	_	_
5-21	423-431	progress	abstract[25]	new[25]	_	_
5-22	432-433	.	_	_	_	_

#Text=Healthcare professionals , and those working in primary health in particular , should aim to educate at-risk patients to lead a healthy lifestyle and use compression stockings .
6-1	434-444	Healthcare	organization|person[27]	giv|giv[27]	coref|coref|coref|coref	9-5|9-5[46_27]|9-5|9-5[46_27]
6-2	445-458	professionals	person[27]	giv[27]	_	_
6-3	459-460	,	_	_	_	_
6-4	461-464	and	_	_	_	_
6-5	465-470	those	abstract	giv	_	_
6-6	471-478	working	_	_	_	_
6-7	479-481	in	_	_	_	_
6-8	482-489	primary	abstract[29]	giv[29]	coref	10-10[0_29]
6-9	490-496	health	abstract[29]	giv[29]	_	_
6-10	497-499	in	_	_	_	_
6-11	500-510	particular	_	_	_	_
6-12	511-512	,	_	_	_	_
6-13	513-519	should	_	_	_	_
6-14	520-523	aim	_	_	_	_
6-15	524-526	to	_	_	_	_
6-16	527-534	educate	_	_	_	_
6-17	535-542	at-risk	abstract|person[31]	new|new[31]	coref|coref	10-8[59_31]|10-8[59_31]
6-18	543-551	patients	person[31]	new[31]	_	_
6-19	552-554	to	_	_	_	_
6-20	555-559	lead	_	_	_	_
6-21	560-561	a	abstract[32]	new[32]	_	_
6-22	562-569	healthy	abstract[32]	new[32]	_	_
6-23	570-579	lifestyle	abstract[32]	new[32]	_	_
6-24	580-583	and	_	_	_	_
6-25	584-587	use	_	_	_	_
6-26	588-599	compression	event|object[34]	new|new[34]	coref|coref|coref|coref	16-11[113_0]|16-43[126_34]|16-11[113_0]|16-43[126_34]
6-27	600-609	stockings	object[34]	new[34]	_	_
6-28	610-611	.	_	_	_	_

#Text=Due to increased awareness of CVD , the tendency is generally for earlier diagnosis and treatment .
7-1	612-615	Due	_	_	_	_
7-2	616-618	to	_	_	_	_
7-3	619-628	increased	abstract[35]	new[35]	_	_
7-4	629-638	awareness	abstract[35]	new[35]	_	_
7-5	639-641	of	abstract[35]	new[35]	_	_
7-6	642-645	CVD	abstract[35]|abstract	new[35]|giv	coref	22-12
7-7	646-647	,	_	_	_	_
7-8	648-651	the	abstract[37]	new[37]	_	_
7-9	652-660	tendency	abstract[37]	new[37]	_	_
7-10	661-663	is	_	_	_	_
7-11	664-673	generally	event[38]|event[39]	new[38]|new[39]	coref|coref|coref|coref	11-11[70_38]|11-11[71_39]|11-11[70_38]|11-11[71_39]
7-12	674-677	for	event[38]|event[39]	new[38]|new[39]	_	_
7-13	678-685	earlier	event[38]|event[39]	new[38]|new[39]	_	_
7-14	686-695	diagnosis	event[38]|event[39]	new[38]|new[39]	_	_
7-15	696-699	and	event[39]	new[39]	_	_
7-16	700-709	treatment	event[39]|event	new[39]|new	coref	11-14
7-17	710-711	.	_	_	_	_

#Text=However , in some countries , the disease is not detected until more advanced stages .
8-1	712-719	However	_	_	_	_
8-2	720-721	,	_	_	_	_
8-3	722-724	in	_	_	_	_
8-4	725-729	some	place[41]	new[41]	_	_
8-5	730-739	countries	place[41]	new[41]	_	_
8-6	740-741	,	_	_	_	_
8-7	742-745	the	abstract[42]	giv[42]	coref	10-22[0_42]
8-8	746-753	disease	abstract[42]	giv[42]	_	_
8-9	754-756	is	_	_	_	_
8-10	757-760	not	_	_	_	_
8-11	761-769	detected	_	_	_	_
8-12	770-775	until	_	_	_	_
8-13	776-780	more	abstract[43]	giv[43]	coref	14-31[96_43]
8-14	781-789	advanced	abstract[43]	giv[43]	_	_
8-15	790-796	stages	abstract[43]	giv[43]	_	_
8-16	797-798	.	_	_	_	_

#Text=There are gaps in healthcare professionals ’ knowledge of venous leg ulcer physiology and its healing process , partly due to a lack of training at a degree level .
9-1	799-804	There	_	_	_	_
9-2	805-808	are	_	_	_	_
9-3	809-813	gaps	abstract[44]	new[44]	_	_
9-4	814-816	in	abstract[44]	new[44]	_	_
9-5	817-827	healthcare	abstract[44]|organization|person[46]|abstract[47]	new[44]|giv|giv[46]|new[47]	coref|coref|coref|coref|coref|coref	10-13|10-13[63_46]|10-13|10-13[63_46]|10-13|10-13[63_46]
9-6	828-841	professionals	abstract[44]|person[46]|abstract[47]	new[44]|giv[46]|new[47]	_	_
9-7	842-843	’	abstract[44]|person[46]|abstract[47]	new[44]|giv[46]|new[47]	_	_
9-8	844-853	knowledge	abstract[44]|abstract[47]	new[44]|new[47]	_	_
9-9	854-856	of	abstract[44]|abstract[47]	new[44]|new[47]	_	_
9-10	857-863	venous	abstract[44]|abstract[47]|place|object[49]	new[44]|new[47]|new|new[49]	coref|coref	20-27|20-27
9-11	864-867	leg	abstract[44]|abstract[47]|object[49]	new[44]|new[47]|new[49]	_	_
9-12	868-873	ulcer	abstract[44]|abstract[47]|person|abstract[51]	new[44]|new[47]|new|new[51]	coref|coref	20-46|20-46
9-13	874-884	physiology	abstract[44]|abstract[47]|abstract[51]	new[44]|new[47]|new[51]	_	_
9-14	885-888	and	abstract[44]|abstract[47]	new[44]|new[47]	_	_
9-15	889-892	its	abstract[44]|abstract[47]|abstract[53]	new[44]|new[47]|new[53]	_	_
9-16	893-900	healing	abstract[44]|abstract[47]|object|abstract[53]	new[44]|new[47]|new|new[53]	_	_
9-17	901-908	process	abstract[44]|abstract[47]|abstract[53]	new[44]|new[47]|new[53]	_	_
9-18	909-910	,	_	_	_	_
9-19	911-917	partly	_	_	_	_
9-20	918-921	due	_	_	_	_
9-21	922-924	to	_	_	_	_
9-22	925-926	a	abstract[54]	new[54]	_	_
9-23	927-931	lack	abstract[54]	new[54]	_	_
9-24	932-934	of	abstract[54]	new[54]	_	_
9-25	935-943	training	abstract[54]|abstract	new[54]|new	_	_
9-26	944-946	at	abstract[54]	new[54]	_	_
9-27	947-948	a	abstract[54]|abstract[57]	new[54]|new[57]	ana	10-17[0_57]
9-28	949-955	degree	abstract[54]|abstract|abstract[57]	new[54]|new|new[57]	_	_
9-29	956-961	level	abstract[54]|abstract[57]	new[54]|new[57]	_	_
9-30	962-963	.	_	_	_	_

#Text=By applying and incorporating this MDS-CVI in patients ’ health records , healthcare professionals will find it easier to monitor the disease course at every stage .
10-1	964-966	By	_	_	_	_
10-2	967-975	applying	_	_	_	_
10-3	976-979	and	_	_	_	_
10-4	980-993	incorporating	_	_	_	_
10-5	994-998	this	object[58]	giv[58]	coref	15-3[100_58]
10-6	999-1006	MDS-CVI	object[58]	giv[58]	_	_
10-7	1007-1009	in	object[58]	giv[58]	_	_
10-8	1010-1018	patients	object[58]|person[59]|object[61]	giv[58]|giv[59]|new[61]	coref|coref	16-25[0_59]|16-25[0_59]
10-9	1019-1020	’	object[58]|person[59]|object[61]	giv[58]|giv[59]|new[61]	_	_
10-10	1021-1027	health	object[58]|abstract|object[61]	giv[58]|giv|new[61]	coref	17-6
10-11	1028-1035	records	object[58]|object[61]	giv[58]|new[61]	_	_
10-12	1036-1037	,	_	_	_	_
10-13	1038-1048	healthcare	organization|person[63]	giv|giv[63]	ana|coref|ana|coref	11-4[0_63]|22-14|11-4[0_63]|22-14
10-14	1049-1062	professionals	person[63]	giv[63]	_	_
10-15	1063-1067	will	_	_	_	_
10-16	1068-1072	find	_	_	_	_
10-17	1073-1075	it	abstract	giv	coref	14-11[89_0]
10-18	1076-1082	easier	_	_	_	_
10-19	1083-1085	to	_	_	_	_
10-20	1086-1093	monitor	_	_	_	_
10-21	1094-1097	the	abstract[66]	new[66]	_	_
10-22	1098-1105	disease	abstract|abstract[66]	giv|new[66]	coref	12-12[77_0]
10-23	1106-1112	course	abstract[66]	new[66]	_	_
10-24	1113-1115	at	_	_	_	_
10-25	1116-1121	every	abstract[67]	new[67]	_	_
10-26	1122-1127	stage	abstract[67]	new[67]	_	_
10-27	1128-1129	.	_	_	_	_

#Text=Above all , they should follow the recommendations to ensure correct diagnosis and treatment .
11-1	1130-1135	Above	_	_	_	_
11-2	1136-1139	all	_	_	_	_
11-3	1140-1141	,	_	_	_	_
11-4	1142-1146	they	person	giv	coref	22-14[177_0]
11-5	1147-1153	should	_	_	_	_
11-6	1154-1160	follow	_	_	_	_
11-7	1161-1164	the	abstract[69]	new[69]	coref	23-1[183_69]
11-8	1165-1180	recommendations	abstract[69]	new[69]	_	_
11-9	1181-1183	to	_	_	_	_
11-10	1184-1190	ensure	_	_	_	_
11-11	1191-1198	correct	event[70]|event[71]	giv[70]|giv[71]	coref|coref	12-16[78_70]|12-16[78_70]
11-12	1199-1208	diagnosis	event[70]|event[71]	giv[70]|giv[71]	_	_
11-13	1209-1212	and	event[71]	giv[71]	_	_
11-14	1213-1222	treatment	event[71]|event	giv[71]|giv	_	_
11-15	1223-1224	.	_	_	_	_

#Text=The CEAP classification system is a very easy method to classify venous disease and reach a reliable diagnosis of CVD/CVI in the population .
12-1	1225-1228	The	abstract[75]	new[75]	coref	12-6[76_75]
12-2	1229-1233	CEAP	organization|abstract[75]	new|new[75]	_	_
12-3	1234-1248	classification	abstract|abstract[75]	new|new[75]	_	_
12-4	1249-1255	system	abstract[75]	new[75]	_	_
12-5	1256-1258	is	_	_	_	_
12-6	1259-1260	a	abstract[76]	giv[76]	coref	13-5[81_76]
12-7	1261-1265	very	abstract[76]	giv[76]	_	_
12-8	1266-1270	easy	abstract[76]	giv[76]	_	_
12-9	1271-1277	method	abstract[76]	giv[76]	_	_
12-10	1278-1280	to	_	_	_	_
12-11	1281-1289	classify	_	_	_	_
12-12	1290-1296	venous	abstract[77]	giv[77]	coref	15-22[0_77]
12-13	1297-1304	disease	abstract[77]	giv[77]	_	_
12-14	1305-1308	and	_	_	_	_
12-15	1309-1314	reach	_	_	_	_
12-16	1315-1316	a	event[78]	giv[78]	_	_
12-17	1317-1325	reliable	event[78]	giv[78]	_	_
12-18	1326-1335	diagnosis	event[78]	giv[78]	_	_
12-19	1336-1338	of	event[78]	giv[78]	_	_
12-20	1339-1346	CVD/CVI	event[78]|abstract	giv[78]|new	_	_
12-21	1347-1349	in	_	_	_	_
12-22	1350-1353	the	person[80]	new[80]	coref	14-8[88_80]
12-23	1354-1364	population	person[80]	new[80]	_	_
12-24	1365-1366	.	_	_	_	_

#Text=The clinical part of the system can be obtained simply by observing a patient ’s legs in the primary care setting .
13-1	1367-1370	The	_	_	_	_
13-2	1371-1379	clinical	_	_	_	_
13-3	1380-1384	part	_	_	_	_
13-4	1385-1387	of	_	_	_	_
13-5	1388-1391	the	abstract[81]	giv[81]	_	_
13-6	1392-1398	system	abstract[81]	giv[81]	_	_
13-7	1399-1402	can	_	_	_	_
13-8	1403-1405	be	_	_	_	_
13-9	1406-1414	obtained	_	_	_	_
13-10	1415-1421	simply	_	_	_	_
13-11	1422-1424	by	_	_	_	_
13-12	1425-1434	observing	_	_	_	_
13-13	1435-1436	a	object[83]	new[83]	_	_
13-14	1437-1444	patient	person[82]|object[83]	new[82]|new[83]	_	_
13-15	1445-1447	’s	person[82]|object[83]	new[82]|new[83]	_	_
13-16	1448-1452	legs	object[83]	new[83]	_	_
13-17	1453-1455	in	object[83]	new[83]	_	_
13-18	1456-1459	the	object[83]|place[85]	new[83]|new[85]	ana	14-1[0_85]
13-19	1460-1467	primary	object[83]|place[85]	new[83]|new[85]	_	_
13-20	1468-1472	care	object[83]|abstract|place[85]	new[83]|new|new[85]	coref	24-8
13-21	1473-1480	setting	object[83]|place[85]	new[83]|new[85]	_	_
13-22	1481-1482	.	_	_	_	_

#Text=It is estimated that 80 % of the population have the mildest level of symptoms ( C1 – C2 , spider and varicose veins ) , while 5 % have the most advanced stages ( C3 – C6 ) .
14-1	1483-1485	It	place	giv	_	_
14-2	1486-1488	is	_	_	_	_
14-3	1489-1498	estimated	_	_	_	_
14-4	1499-1503	that	_	_	_	_
14-5	1504-1506	80	quantity[87]	new[87]	_	_
14-6	1507-1508	%	quantity[87]	new[87]	_	_
14-7	1509-1511	of	quantity[87]	new[87]	_	_
14-8	1512-1515	the	quantity[87]|person[88]	new[87]|giv[88]	coref	15-17[104_88]
14-9	1516-1526	population	quantity[87]|person[88]	new[87]|giv[88]	_	_
14-10	1527-1531	have	_	_	_	_
14-11	1532-1535	the	abstract[89]	giv[89]	_	_
14-12	1536-1543	mildest	abstract[89]	giv[89]	_	_
14-13	1544-1549	level	abstract[89]	giv[89]	_	_
14-14	1550-1552	of	abstract[89]	giv[89]	_	_
14-15	1553-1561	symptoms	abstract[89]|abstract	giv[89]|new	appos	14-17[91_0]
14-16	1562-1563	(	_	_	_	_
14-17	1564-1566	C1	abstract[91]	giv[91]	appos	14-21[0_91]
14-18	1567-1568	–	abstract[91]	giv[91]	_	_
14-19	1569-1571	C2	abstract[91]|abstract	giv[91]|new	_	_
14-20	1572-1573	,	_	_	_	_
14-21	1574-1580	spider	abstract	giv	_	_
14-22	1581-1584	and	_	_	_	_
14-23	1585-1593	varicose	object[94]	new[94]	_	_
14-24	1594-1599	veins	object[94]	new[94]	_	_
14-25	1600-1601	)	_	_	_	_
14-26	1602-1603	,	_	_	_	_
14-27	1604-1609	while	_	_	_	_
14-28	1610-1611	5	quantity[95]	new[95]	_	_
14-29	1612-1613	%	quantity[95]	new[95]	_	_
14-30	1614-1618	have	_	_	_	_
14-31	1619-1622	the	abstract[96]	giv[96]	ana	15-30[0_96]
14-32	1623-1627	most	abstract[96]	giv[96]	_	_
14-33	1628-1636	advanced	abstract[96]	giv[96]	_	_
14-34	1637-1643	stages	abstract[96]	giv[96]	_	_
14-35	1644-1645	(	_	_	_	_
14-36	1646-1648	C3	abstract[97]	new[97]	_	_
14-37	1649-1650	–	abstract[97]	new[97]	_	_
14-38	1651-1653	C6	abstract[97]|abstract	new[97]|new	_	_
14-39	1654-1655	)	_	_	_	_
14-40	1656-1657	.	_	_	_	_

#Text=Implementation of this evidence-based MDS-CVI would result in more reliable data collection and facilitate monitoring of a specific population to observe disease progression , the treatments used , and their effectiveness .
15-1	1658-1672	Implementation	abstract[99]	new[99]	_	_
15-2	1673-1675	of	abstract[99]	new[99]	_	_
15-3	1676-1680	this	abstract[99]|object[100]	new[99]|giv[100]	coref	17-1[127_100]
15-4	1681-1695	evidence-based	abstract[99]|object[100]	new[99]|giv[100]	_	_
15-5	1696-1703	MDS-CVI	abstract[99]|object[100]	new[99]|giv[100]	_	_
15-6	1704-1709	would	_	_	_	_
15-7	1710-1716	result	_	_	_	_
15-8	1717-1719	in	_	_	_	_
15-9	1720-1724	more	abstract[102]	new[102]	_	_
15-10	1725-1733	reliable	abstract[102]	new[102]	_	_
15-11	1734-1738	data	abstract|abstract[102]	new|new[102]	_	_
15-12	1739-1749	collection	abstract[102]	new[102]	_	_
15-13	1750-1753	and	_	_	_	_
15-14	1754-1764	facilitate	_	_	_	_
15-15	1765-1775	monitoring	event[103]	new[103]	_	_
15-16	1776-1778	of	event[103]	new[103]	_	_
15-17	1779-1780	a	event[103]|person[104]	new[103]|giv[104]	coref	17-17[132_104]
15-18	1781-1789	specific	event[103]|person[104]	new[103]|giv[104]	_	_
15-19	1790-1800	population	event[103]|person[104]	new[103]|giv[104]	_	_
15-20	1801-1803	to	_	_	_	_
15-21	1804-1811	observe	_	_	_	_
15-22	1812-1819	disease	abstract|abstract[106]	giv|new[106]	appos|coref|appos|coref	15-25[107_106]|19-8[141_0]|15-25[107_106]|19-8[141_0]
15-23	1820-1831	progression	abstract[106]	new[106]	_	_
15-24	1832-1833	,	_	_	_	_
15-25	1834-1837	the	abstract[107]	giv[107]	coref	23-16[189_107]
15-26	1838-1848	treatments	abstract[107]	giv[107]	_	_
15-27	1849-1853	used	_	_	_	_
15-28	1854-1855	,	_	_	_	_
15-29	1856-1859	and	_	_	_	_
15-30	1860-1865	their	abstract|abstract[109]	giv|new[109]	_	_
15-31	1866-1879	effectiveness	abstract[109]	new[109]	_	_
15-32	1880-1881	.	_	_	_	_

#Text=With the existing level of evidence of the importance of therapeutic compression of the lower limbs , it is unacceptable that 90 % of patients with CVI in Turkey and 54 % of patients with venous ulcers in Spain are not given compression stockings .
16-1	1882-1886	With	_	_	_	_
16-2	1887-1890	the	abstract[110]	new[110]	_	_
16-3	1891-1899	existing	abstract[110]	new[110]	_	_
16-4	1900-1905	level	abstract[110]	new[110]	_	_
16-5	1906-1908	of	abstract[110]	new[110]	_	_
16-6	1909-1917	evidence	abstract[110]|abstract[111]	new[110]|new[111]	_	_
16-7	1918-1920	of	abstract[110]|abstract[111]	new[110]|new[111]	_	_
16-8	1921-1924	the	abstract[110]|abstract[111]|abstract[112]	new[110]|new[111]|new[112]	ana	16-18[0_112]
16-9	1925-1935	importance	abstract[110]|abstract[111]|abstract[112]	new[110]|new[111]|new[112]	_	_
16-10	1936-1938	of	abstract[110]|abstract[111]|abstract[112]	new[110]|new[111]|new[112]	_	_
16-11	1939-1950	therapeutic	abstract[110]|abstract[111]|abstract[112]|event[113]	new[110]|new[111]|new[112]|giv[113]	coref	16-43[0_113]
16-12	1951-1962	compression	abstract[110]|abstract[111]|abstract[112]|event[113]	new[110]|new[111]|new[112]|giv[113]	_	_
16-13	1963-1965	of	abstract[110]|abstract[111]|abstract[112]|event[113]	new[110]|new[111]|new[112]|giv[113]	_	_
16-14	1966-1969	the	abstract[110]|abstract[111]|abstract[112]|event[113]|object[114]	new[110]|new[111]|new[112]|giv[113]|new[114]	_	_
16-15	1970-1975	lower	abstract[110]|abstract[111]|abstract[112]|event[113]|object[114]	new[110]|new[111]|new[112]|giv[113]|new[114]	_	_
16-16	1976-1981	limbs	abstract[110]|abstract[111]|abstract[112]|event[113]|object[114]	new[110]|new[111]|new[112]|giv[113]|new[114]	_	_
16-17	1982-1983	,	_	_	_	_
16-18	1984-1986	it	abstract	giv	_	_
16-19	1987-1989	is	_	_	_	_
16-20	1990-2002	unacceptable	_	_	_	_
16-21	2003-2007	that	person[124]	new[124]	_	_
16-22	2008-2010	90	quantity[116]|person[124]	new[116]|new[124]	_	_
16-23	2011-2012	%	quantity[116]|person[124]	new[116]|new[124]	_	_
16-24	2013-2015	of	quantity[116]|person[124]	new[116]|new[124]	_	_
16-25	2016-2024	patients	quantity[116]|person|person[124]	new[116]|giv|new[124]	coref	16-34[121_0]
16-26	2025-2029	with	quantity[116]|person[124]	new[116]|new[124]	_	_
16-27	2030-2033	CVI	quantity[116]|abstract[118]|person[124]	new[116]|new[118]|new[124]	coref	18-3[0_118]
16-28	2034-2036	in	quantity[116]|abstract[118]|person[124]	new[116]|new[118]|new[124]	_	_
16-29	2037-2043	Turkey	quantity[116]|abstract[118]|place|person[124]	new[116]|new[118]|new|new[124]	_	_
16-30	2044-2047	and	person[124]	new[124]	_	_
16-31	2048-2050	54	quantity[120]|person[124]	new[120]|new[124]	_	_
16-32	2051-2052	%	quantity[120]|person[124]	new[120]|new[124]	_	_
16-33	2053-2055	of	quantity[120]|person[124]	new[120]|new[124]	_	_
16-34	2056-2064	patients	quantity[120]|person[121]|person[124]	new[120]|giv[121]|new[124]	coref	20-11[145_121]
16-35	2065-2069	with	quantity[120]|person[121]|person[124]	new[120]|giv[121]|new[124]	_	_
16-36	2070-2076	venous	quantity[120]|person[121]|object[122]|person[124]	new[120]|giv[121]|new[122]|new[124]	coref	20-51[165_122]
16-37	2077-2083	ulcers	quantity[120]|person[121]|object[122]|person[124]	new[120]|giv[121]|new[122]|new[124]	_	_
16-38	2084-2086	in	quantity[120]|person[121]|object[122]|person[124]	new[120]|giv[121]|new[122]|new[124]	_	_
16-39	2087-2092	Spain	quantity[120]|person[121]|object[122]|place|person[124]	new[120]|giv[121]|new[122]|new|new[124]	coref	17-13[131_0]
16-40	2093-2096	are	person[124]	new[124]	_	_
16-41	2097-2100	not	person[124]	new[124]	_	_
16-42	2101-2106	given	person[124]	new[124]	_	_
16-43	2107-2118	compression	person[124]|event|object[126]	new[124]|giv|giv[126]	_	_
16-44	2119-2128	stockings	person[124]|object[126]	new[124]|giv[126]	_	_
16-45	2129-2130	.	_	_	_	_

#Text=The MDS-CVI will also permit health managers to plan interventions according to the venous state of the population and identify which quality indicators should be applied .
17-1	2131-2134	The	abstract[127]	giv[127]	_	_
17-2	2135-2142	MDS-CVI	abstract[127]	giv[127]	_	_
17-3	2143-2147	will	_	_	_	_
17-4	2148-2152	also	_	_	_	_
17-5	2153-2159	permit	_	_	_	_
17-6	2160-2166	health	abstract|person[129]	giv|new[129]	_	_
17-7	2167-2175	managers	person[129]	new[129]	_	_
17-8	2176-2178	to	_	_	_	_
17-9	2179-2183	plan	_	_	_	_
17-10	2184-2197	interventions	event[130]	new[130]	_	_
17-11	2198-2207	according	event[130]	new[130]	_	_
17-12	2208-2210	to	event[130]	new[130]	_	_
17-13	2211-2214	the	event[130]|place[131]	new[130]|giv[131]	_	_
17-14	2215-2221	venous	event[130]|place[131]	new[130]|giv[131]	_	_
17-15	2222-2227	state	event[130]|place[131]	new[130]|giv[131]	_	_
17-16	2228-2230	of	event[130]|place[131]	new[130]|giv[131]	_	_
17-17	2231-2234	the	event[130]|place[131]|person[132]	new[130]|giv[131]|giv[132]	_	_
17-18	2235-2245	population	event[130]|place[131]|person[132]	new[130]|giv[131]|giv[132]	_	_
17-19	2246-2249	and	_	_	_	_
17-20	2250-2258	identify	_	_	_	_
17-21	2259-2264	which	_	_	_	_
17-22	2265-2272	quality	abstract|abstract[134]	new|new[134]	coref|coref	18-5[137_0]|18-5[137_0]
17-23	2273-2283	indicators	abstract[134]	new[134]	_	_
17-24	2284-2290	should	_	_	_	_
17-25	2291-2293	be	_	_	_	_
17-26	2294-2301	applied	_	_	_	_
17-27	2302-2303	.	_	_	_	_

#Text=People with CVI have a poor quality of life .
18-1	2304-2310	People	person[135]	new[135]	_	_
18-2	2311-2315	with	person[135]	new[135]	_	_
18-3	2316-2319	CVI	person[135]|abstract	new[135]|giv	coref	20-39
18-4	2320-2324	have	_	_	_	_
18-5	2325-2326	a	abstract[137]	giv[137]	_	_
18-6	2327-2331	poor	abstract[137]	giv[137]	_	_
18-7	2332-2339	quality	abstract[137]	giv[137]	_	_
18-8	2340-2342	of	abstract[137]	giv[137]	_	_
18-9	2343-2347	life	abstract[137]|abstract	giv[137]|new	coref	20-9[144_0]
18-10	2348-2349	.	_	_	_	_

#Text=It is therefore important to determine how the venous disease affects each individual .
19-1	2350-2352	It	abstract	new	cata	19-1[0_140]
19-2	2353-2355	is	_	_	_	_
19-3	2356-2365	therefore	_	_	_	_
19-4	2366-2375	important	_	_	_	_
19-5	2376-2378	to	abstract[140]	new[140]	_	_
19-6	2379-2388	determine	abstract[140]	new[140]	_	_
19-7	2389-2392	how	abstract[140]	new[140]	_	_
19-8	2393-2396	the	abstract[140]|abstract[141]	new[140]|giv[141]	_	_
19-9	2397-2403	venous	abstract[140]|abstract[141]	new[140]|giv[141]	_	_
19-10	2404-2411	disease	abstract[140]|abstract[141]	new[140]|giv[141]	_	_
19-11	2412-2419	affects	abstract[140]	new[140]	_	_
19-12	2420-2424	each	abstract[140]	new[140]	_	_
19-13	2425-2435	individual	abstract[140]	new[140]	_	_
19-14	2436-2437	.	_	_	_	_

#Text=Specific instruments are available to measure quality of life in these patients , such as the Aberdeen Varicose Vein Questionnaire ( AVVQ ) or the Chronic Venous Insufficiency Quality of Life Questionnaire ( CIVIC ) for patients with CVI , and the Charing Cross Venous Ulcer Questionnaire for patients with venous ulcers .
20-1	2438-2446	Specific	object[142]	new[142]	coref	21-1[166_142]
20-2	2447-2458	instruments	object[142]	new[142]	_	_
20-3	2459-2462	are	_	_	_	_
20-4	2463-2472	available	_	_	_	_
20-5	2473-2475	to	_	_	_	_
20-6	2476-2483	measure	_	_	_	_
20-7	2484-2491	quality	abstract[143]	new[143]	_	_
20-8	2492-2494	of	abstract[143]	new[143]	_	_
20-9	2495-2499	life	abstract[143]|abstract[144]	new[143]|giv[144]	_	_
20-10	2500-2502	in	abstract[143]|abstract[144]	new[143]|giv[144]	_	_
20-11	2503-2508	these	abstract[143]|abstract[144]|person[145]	new[143]|giv[144]|giv[145]	coref	20-37[158_145]
20-12	2509-2517	patients	abstract[143]|abstract[144]|person[145]	new[143]|giv[144]|giv[145]	_	_
20-13	2518-2519	,	abstract[143]	new[143]	_	_
20-14	2520-2524	such	abstract[143]	new[143]	_	_
20-15	2525-2527	as	abstract[143]	new[143]	_	_
20-16	2528-2531	the	abstract[143]|abstract[149]	new[143]|new[149]	appos	20-22[0_149]
20-17	2532-2540	Aberdeen	abstract[143]|place|abstract[149]	new[143]|new|new[149]	_	_
20-18	2541-2549	Varicose	abstract[143]|animal|abstract[149]	new[143]|new|new[149]	_	_
20-19	2550-2554	Vein	abstract[143]|plant|abstract[149]	new[143]|new|new[149]	_	_
20-20	2555-2568	Questionnaire	abstract[143]|abstract[149]	new[143]|new[149]	_	_
20-21	2569-2570	(	_	_	_	_
20-22	2571-2575	AVVQ	abstract	giv	coref	20-31[156_0]
20-23	2576-2577	)	_	_	_	_
20-24	2578-2580	or	_	_	_	_
20-25	2581-2584	the	abstract[154]	new[154]	coref	24-7[0_154]
20-26	2585-2592	Chronic	person|abstract[154]	new|new[154]	_	_
20-27	2593-2599	Venous	person|abstract[154]	giv|new[154]	coref	20-45
20-28	2600-2613	Insufficiency	abstract|abstract[154]	new|new[154]	_	_
20-29	2614-2621	Quality	abstract[154]	new[154]	_	_
20-30	2622-2624	of	abstract[154]	new[154]	_	_
20-31	2625-2629	Life	abstract[154]|time|abstract[156]	new[154]|new|giv[156]	coref|coref	20-42[164_156]|20-42[164_156]
20-32	2630-2643	Questionnaire	abstract[154]|abstract[156]	new[154]|giv[156]	_	_
20-33	2644-2645	(	_	_	_	_
20-34	2646-2651	CIVIC	object	new	_	_
20-35	2652-2653	)	_	_	_	_
20-36	2654-2657	for	_	_	_	_
20-37	2658-2666	patients	person[158]	giv[158]	_	_
20-38	2667-2671	with	person[158]	giv[158]	_	_
20-39	2672-2675	CVI	person[158]|abstract	giv[158]|giv	coref	24-4
20-40	2676-2677	,	person[158]	giv[158]	_	_
20-41	2678-2681	and	person[158]	giv[158]	_	_
20-42	2682-2685	the	person[158]|abstract[164]	giv[158]|giv[164]	_	_
20-43	2686-2693	Charing	person[158]|abstract|abstract[164]	giv[158]|new|giv[164]	_	_
20-44	2694-2699	Cross	person[158]|person|abstract[164]	giv[158]|new|giv[164]	_	_
20-45	2700-2706	Venous	person[158]|person|abstract[164]	giv[158]|giv|giv[164]	coref	23-12
20-46	2707-2712	Ulcer	person[158]|person|abstract[164]	giv[158]|giv|giv[164]	_	_
20-47	2713-2726	Questionnaire	person[158]|abstract[164]	giv[158]|giv[164]	_	_
20-48	2727-2730	for	person[158]|abstract[164]	giv[158]|giv[164]	_	_
20-49	2731-2739	patients	person[158]|abstract[164]	giv[158]|giv[164]	_	_
20-50	2740-2744	with	person[158]|abstract[164]	giv[158]|giv[164]	_	_
20-51	2745-2751	venous	person[158]|abstract[164]|object[165]	giv[158]|giv[164]|giv[165]	_	_
20-52	2752-2758	ulcers	person[158]|abstract[164]|object[165]	giv[158]|giv[164]|giv[165]	_	_
20-53	2759-2760	.	_	_	_	_

#Text=The instruments are valid for only certain languages and cultures and they therefore need to be adapted to be effective .
21-1	2761-2764	The	object[166]	giv[166]	_	_
21-2	2765-2776	instruments	object[166]	giv[166]	_	_
21-3	2777-2780	are	_	_	_	_
21-4	2781-2786	valid	_	_	_	_
21-5	2787-2790	for	_	_	_	_
21-6	2791-2795	only	abstract[167]	new[167]	_	_
21-7	2796-2803	certain	abstract[167]	new[167]	_	_
21-8	2804-2813	languages	abstract[167]	new[167]	_	_
21-9	2814-2817	and	_	_	_	_
21-10	2818-2826	cultures	abstract	new	ana	21-12
21-11	2827-2830	and	_	_	_	_
21-12	2831-2835	they	abstract	giv	_	_
21-13	2836-2845	therefore	_	_	_	_
21-14	2846-2850	need	_	_	_	_
21-15	2851-2853	to	_	_	_	_
21-16	2854-2856	be	_	_	_	_
21-17	2857-2864	adapted	_	_	_	_
21-18	2865-2867	to	_	_	_	_
21-19	2868-2870	be	_	_	_	_
21-20	2871-2880	effective	_	_	_	_
21-21	2881-2882	.	_	_	_	_

#Text=Non-pharmacological measures are essential in the prevention and adjuvant therapy of CVD and healthcare professionals should therefore be aware of their existence and use them in their clinical practice .
22-1	2883-2902	Non-pharmacological	abstract[170]	new[170]	_	_
22-2	2903-2911	measures	abstract[170]	new[170]	_	_
22-3	2912-2915	are	_	_	_	_
22-4	2916-2925	essential	_	_	_	_
22-5	2926-2928	in	_	_	_	_
22-6	2929-2932	the	abstract[171]|abstract[172]	new[171]|new[172]	ana|ana	22-21[0_172]|22-21[0_172]
22-7	2933-2943	prevention	abstract[171]|abstract[172]	new[171]|new[172]	_	_
22-8	2944-2947	and	abstract[172]	new[172]	_	_
22-9	2948-2956	adjuvant	abstract[172]|abstract|abstract[174]	new[172]|new|new[174]	_	_
22-10	2957-2964	therapy	abstract[172]|abstract[174]	new[172]|new[174]	_	_
22-11	2965-2967	of	abstract[172]|abstract[174]	new[172]|new[174]	_	_
22-12	2968-2971	CVD	abstract[172]|abstract[174]|event	new[172]|new[174]|giv	_	_
22-13	2972-2975	and	_	_	_	_
22-14	2976-2986	healthcare	organization|person[177]	giv|giv[177]	_	_
22-15	2987-3000	professionals	person[177]	giv[177]	_	_
22-16	3001-3007	should	_	_	_	_
22-17	3008-3017	therefore	_	_	_	_
22-18	3018-3020	be	_	_	_	_
22-19	3021-3026	aware	_	_	_	_
22-20	3027-3029	of	_	_	_	_
22-21	3030-3035	their	abstract|abstract[179]	giv|new[179]	ana|ana	22-25|22-25
22-22	3036-3045	existence	abstract[179]	new[179]	_	_
22-23	3046-3049	and	_	_	_	_
22-24	3050-3053	use	_	_	_	_
22-25	3054-3058	them	abstract	giv	ana	22-27
22-26	3059-3061	in	_	_	_	_
22-27	3062-3067	their	abstract|abstract[182]	giv|new[182]	_	_
22-28	3068-3076	clinical	abstract[182]	new[182]	_	_
22-29	3077-3085	practice	abstract[182]	new[182]	_	_
22-30	3086-3087	.	_	_	_	_

#Text=Recommendations such as weight loss or taking regular exercise will help venous return and delay symptom progression .
23-1	3088-3103	Recommendations	abstract[183]	giv[183]	_	_
23-2	3104-3108	such	abstract[183]	giv[183]	_	_
23-3	3109-3111	as	abstract[183]	giv[183]	_	_
23-4	3112-3118	weight	abstract[183]|abstract[184]	giv[183]|new[184]	_	_
23-5	3119-3123	loss	abstract[183]|abstract[184]	giv[183]|new[184]	_	_
23-6	3124-3126	or	_	_	_	_
23-7	3127-3133	taking	_	_	_	_
23-8	3134-3141	regular	event[185]	new[185]	_	_
23-9	3142-3150	exercise	event[185]	new[185]	_	_
23-10	3151-3155	will	_	_	_	_
23-11	3156-3160	help	_	_	_	_
23-12	3161-3167	venous	quantity|event[187]	giv|new[187]	_	_
23-13	3168-3174	return	event[187]	new[187]	_	_
23-14	3175-3178	and	_	_	_	_
23-15	3179-3184	delay	_	_	_	_
23-16	3185-3192	symptom	abstract|abstract[189]	new|giv[189]	_	_
23-17	3193-3204	progression	abstract[189]	giv[189]	_	_
23-18	3205-3206	.	_	_	_	_

#Text=The MDS for CVI establishes minimum quality care criteria and can help to guide in the purchase of necessary services .
24-1	3207-3210	The	abstract[190]	new[190]	_	_
24-2	3211-3214	MDS	abstract[190]	new[190]	_	_
24-3	3215-3218	for	abstract[190]	new[190]	_	_
24-4	3219-3222	CVI	abstract[190]|organization	new[190]|giv	_	_
24-5	3223-3234	establishes	_	_	_	_
24-6	3235-3242	minimum	abstract[194]	new[194]	_	_
24-7	3243-3250	quality	abstract|abstract[194]	giv|new[194]	_	_
24-8	3251-3255	care	abstract|abstract[194]	giv|new[194]	_	_
24-9	3256-3264	criteria	abstract[194]	new[194]	_	_
24-10	3265-3268	and	_	_	_	_
24-11	3269-3272	can	_	_	_	_
24-12	3273-3277	help	_	_	_	_
24-13	3278-3280	to	_	_	_	_
24-14	3281-3286	guide	_	_	_	_
24-15	3287-3289	in	_	_	_	_
24-16	3290-3293	the	event[195]	new[195]	_	_
24-17	3294-3302	purchase	event[195]	new[195]	_	_
24-18	3303-3305	of	event[195]	new[195]	_	_
24-19	3306-3315	necessary	event[195]|abstract[196]	new[195]|new[196]	_	_
24-20	3316-3324	services	event[195]|abstract[196]	new[195]|new[196]	_	_
24-21	3325-3326	.	_	_	_	_
